Once-daily darunavir/ritonavir 400/100 mg in triple therapy : efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:85 |
|---|---|
| Enthalten in: |
British journal of clinical pharmacology - 85(2019), 1 vom: 30. Jan., Seite 277-280 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lê, Minh P [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.12.2019 Date Revised 09.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bcp.13796 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM290540135 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM290540135 | ||
| 003 | DE-627 | ||
| 005 | 20231225064947.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bcp.13796 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0968.xml |
| 035 | |a (DE-627)NLM290540135 | ||
| 035 | |a (NLM)30421447 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lê, Minh P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Once-daily darunavir/ritonavir 400/100 mg in triple therapy |b efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.12.2019 | ||
| 500 | |a Date Revised 09.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a darunavir | |
| 650 | 4 | |a dose reduction | |
| 650 | 4 | |a seminal and blood plasma | |
| 650 | 4 | |a unbound total | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 650 | 7 | |a Reverse Transcriptase Inhibitors |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Darunavir |2 NLM | |
| 650 | 7 | |a YO603Y8113 |2 NLM | |
| 700 | 1 | |a Chaix, Marie-Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Raffi, François |e verfasserin |4 aut | |
| 700 | 1 | |a Chevret, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Gallien, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Katlama, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Delobel, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Yazdanpanah, Yazdan |e verfasserin |4 aut | |
| 700 | 1 | |a Saillard, Juliette |e verfasserin |4 aut | |
| 700 | 1 | |a Molina, Jean-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Peytavin, Gilles |e verfasserin |4 aut | |
| 700 | 0 | |a ANRS-165 DARULIGHT study group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d 1974 |g 85(2019), 1 vom: 30. Jan., Seite 277-280 |w (DE-627)NLM000097799 |x 1365-2125 |7 nnns |
| 773 | 1 | 8 | |g volume:85 |g year:2019 |g number:1 |g day:30 |g month:01 |g pages:277-280 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcp.13796 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 85 |j 2019 |e 1 |b 30 |c 01 |h 277-280 | ||